| Description |
AZD4694, a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (Kd = 2.3 nM)[1].
|
| Related Catalog |
|
| Target |
Kd: 2.3 nM (Aβ)
|
| In Vivo |
Administration of unlabeled AZD4694 to rat showed that it has a pharmacokinetic profile consistent with good PET radioligands, it quickly entered and rapidly cleared from normal rat brain tissue[1]. AZD4694 (4 mL/kg; intravenous injection) inhibits [3H]AZD2184 binding (1 nM) in a concentration-dependent manner, with a Ki of 23.1 nM, in postmortem brain sections from AD patients[1]. Animal Model: Male Sprague–Dawley rats (275-300 g)[1] Dosage: 4 mL/kg Administration: I.v. Result: Inhibited [3H]AZD2184 binding in a concentration-dependent manner, with a Ki of 23.1 nM, in postmortem brain sections from AD patients.
|
| References |
[1]. Juréus A, Swahn BM, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114(3):784-794.
|
![[6-fluoro-5-(5-methoxy-benzofuran-2-yl)-pyridin-2-yl]-methyl-carbamic acid tert-butyl ester structure](https://www.chemsrc.com/caspic/455/1054629-59-2.png)
